

AMENDMENTS

Claims 1-6 and 8-17 are pending.

Claims 4, 9 and 15 have been amended.

Claim 7 has been cancelled.

Claims 1-3, 5, 8, 11, and 13 have been withdrawn.

Support for the amendments of Claims 4, 9, and 15 can be found in the original claims. No new matter is believed to have been added.

REMARKS AND REQUEST FOR RECONSIDERATION

The claims are rejected under 35 U.S.C. 102(b) and 103(a) over Yoshizawa, JP 60246309, because the Examiner is of the opinion that Yoshizawa's liquid composition comprising 0.1-0.3 wt.% of lemon juice for the treatment of the skin inherently increases an expression level of Rho kinase or myosin light-chain kinase in the skin.

Claims 4, 9, and 15 have been amended to be directed to a method of treating aging of the skin comprising contacting the skin with an agent comprising a plant, a part of the plant, and/or an extract of *Digeneasimplex*.

Yoshizawa do not describe or suggest using *Digeneasimplex* as an aging treating agent increasing an expression level of Rho kinase or myosin light-chain kinase in the skin.

Applicants request that the rejection be withdrawn.

This application presents allowable subject matter, and the Examiner is kindly requested to pass it to issue.

Should the Examiner have any questions regarding the claims or otherwise wish to discuss this case, he is kindly invited to contact Applicants' below-signed representative, who would be happy to provide any assistance deemed necessary in speeding this application to allowance.

Application No. 10/791,753
Reply to Office Action of July 28, 2008

A Notice of Allowance for all pending claims is requested.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Marina I. Miller, Ph.D
Attorney of Record
Registration No. 59,091

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/07)